Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
Journal of Psychiatric Research May 1, 2023 Franklin R. Schneier, Jamie D. Feusner, Michael G. Wheaton et al. 79 citations
Body dysmorphic disorder (BDD) is an often-severe condition in which individuals are preoccupied by misperceptions of their appearance as defective or ugly. Only serotonin reuptake inhibitors and cognitive-behavioral therapy have been demonstrated efficacious in randomized controlled trials. Psilocybin is a psychedelic drug with growing evidence for safety and efficacy in treatment of...
DOI: 10.1016/j.jpsychires.2023.03.031 (opens in new tab)
Full text (opens in new tab)
Psilocybin
Body dysmorphic disorder
Clinical trial
Psychedelic treatment
+4